Caseiro, O, Perez-Iglesias, R, Mata, I, et al. Predicting relapse after a first episode of non-affective psychosis: a three-year follow-up study. J Psychiatr Res. 2012; 46(8): 1099–1105.
Hasan, A, Falkai, P, Wobrock, T, et al. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, part 2: update 2012 on the long-term treatment of schizophrenia and management of antipsychotic-induced side effects. World J Biol Psychiatry. 2013; 14(1): 2–44.
Kreyenbuhl, J, Buchanan, RW, Dickerson, FB, Dixon, LB, Schizophrenia Patient Outcomes Research Team. The Schizophrenia Patient Outcomes Research Team (PORT): updated treatment recommendations 2009. Schizophr Bull. 2010; 36(1): 94–103.
Velligan, DI, Weiden, PJ, Sajatovic, M, et al. The expert consensus guideline series: adherence problems in patients with serious and persistent mental illness. J Clin Psychiatry. 2009; 70(Suppl 4): 1–46; quiz 47–48.
Dibonaventura, M, Gabriel, S, Dupclay, L, Gupta, S, Kim, E. A patient perspective of the impact of medication side effects on adherence: results of a cross-sectional nationwide survey of patients with schizophrenia. BMC Psychiatry. 2012; 12: 20.
Ascher-Svanum, H, Faries, DE, Zhu, B, et al. Medication adherence and long-term functional outcomes in the treatment of schizophrenia in usual care. J Clin Psychiatry. 2006; 67(3): 453–460.
Weiden, PJ, Kozma, C, Grogg, A, Locklear, J. Partial compliance and risk of rehospitalization among California Medicaid patients with schizophrenia. Psychiatr Serv. 2004; 55(8): 886–891.
Haddad, PM, Brain, C, Scott, J. Nonadherence with antipsychotic medication in schizophrenia: challenges and management strategies. Patient Relat Outcome Meas. 2014; 5: 43–62.
Asseburg, C, Willis, M, Lothgren, M, et al. Hospitalisation utilisation and costs in schizophrenia patients in Finland before and after initiation of risperidone long-acting injection. Schizophr Res Treat. 2012; 2012: 791468.
Kane, JM, Zhao, C, Johnson, BR, et al. Hospitalization rates in patients switched from oral anti-psychotics to aripiprazole once-monthly: final efficacy analysis. J Med Econ. 2015; 18(2): 145–154.
Kishimoto, T, Nitta, M, Borenstein, M, Kane, JM, Correll, CU. Long-acting injectable versus oral antipsychotics in schizophrenia: a systematic review and meta-analysis of mirror-image studies. J Clin Psychiatry. 2013; 74(10): 957–965.
Taylor, D, Olofinjana, O. Long-acting paliperidone palmitate—interim results of an observational study of its effect on hospitalization. Int Clin Psychopharmacol. 2014; 29(4): 229–234.
Kane, J, Sanchez, R, Perry, P, et al. Aripiprazole intramuscular depot as maintenance treatment in patients with schizophrenia: a 52-week multicenter, randomized, double-blind, placebo-controlled study. J Clin Psychiatry. 2012; 73(5): 617–624.
Fleischhacker, WW, Sanchez, R, Perry, PP, et al. Aripiprazole once-monthly for treatment of schizophrenia: double-blind, randomised, non-inferiority study. Br J Psychiatry. 2014; 205(2): 135–144.
Kane, JM, Peters-Strickland, T, Baker, RA, et al. Aripiprazole once-monthly in the acute treatment of schizophrenia: findings from a 12-week, randomized, double-blind, placebo-controlled study. J Clin Psychiatry. 2014; 75(11): 1254–1260.
Singal, AG, Higgins, PD, Waljee, AK. A primer on effectiveness and efficacy trials. Clin Transl Gastroenterol. 2014; 5: e45.
Kishimoto, T, Robenzadeh, A, Leucht, C, et al. Long-acting injectable vs oral antipsychotics for relapse prevention in schizophrenia: a meta-analysis of randomized trials. Schizophr Bull. 2014; 40(1): 192–213.
Kane, JM, Sanchez, R, Zhao, J, et al. Hospitalisation rates in patients switched from oral anti-psychotics to aripiprazole once-monthly for the management of schizophrenia. J Med Econ. 2013; 16(7): 917–925.
Kay, SR, Fiszbein, A, Opler, LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull. 1987; 13(2): 261–276.
Guy, W. Clinical Global Impression Scale (CGI). In. ECDEU Assessment Manual for Psychopharmacology. Rockville, MD: U.S. Department of Health, Education, and Welfare, Public Health Service, Alcohol, Drug Abuse, and Mental Health Administration, National Institute of Mental Health, Psychopharmacology Research Branch, Division of Extramural Research Programs; 1976: 217–222.
Guy, W. ECDEU Assessment Manual for Psychopharmacology—Revised. Rockville, MD: U.S. Department of Health Services; 1976.
Rosa, F, Schreiner, A, Thomas, P, Sherif, T. Switching patients with stable schizophrenia or schizoaffective disorder from olanzapine to risperidone long-acting injectable. Clin Drug Investig. 2012; 32(4): 267–279.